Avanos Medical (AVNS) Net Income towards Common Stockholders (2013 - 2026)

Avanos Medical has disclosed Net Income towards Common Stockholders across 14 years of filings, most recently posting $5.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 22.73% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at -$74.4 million (up 80.66% YoY), while the FY2025 annual figure was -$72.9 million, up 81.41% from the prior year.
• Net Income towards Common Stockholders came in at $5.1 million for Q1 2026 at Avanos Medical, up from -$1.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $16.9 million in Q4 2022 to a low of -$397.3 million in Q4 2024.
• Average Net Income towards Common Stockholders over 5 years is -$27.7 million, with a median of $1.8 million recorded in 2024.
• The largest YoY upside for Net Income towards Common Stockholders was 833.33% in 2025 against a maximum downside of 4366.67% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $16.9 million in 2022, then tumbled by 37.87% to $10.5 million in 2023, then slumped by 3883.81% to -$397.3 million in 2024, then surged by 99.67% to -$1.3 million in 2025, then surged by 492.31% to $5.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $5.1 million in Q1 2026, -$1.3 million in Q4 2025, and -$1.4 million in Q3 2025.